tbuckley/cabot-search huggingface dataset:
Abstract 8696: Assessment of Time-Left Atrial Volume Curve and Left Atrial Emptying Function by Speckle Tracking Echocardiography is Useful to Evaluate Left Ventricular Diastolic Function in Patients with Preserved Ejection Fraction
Authors: Tomoko Fujii, Ryuhei Tanaka, Koji Ono, Takatomo Watanabe, Maki Nagaya, Noriyuki Onishi, Reiko Matsuoka, Fumitaka Tokoro, Shintaro Abe, Yoshiaki Goto, Takashi Yoshizane, Takashi Kato, Syunichiro Warita, Tai Kojima, Makoto Iwama, Takeshi Hirose, Shintaro Tanihata, Toshiyuki Noda, Mami Iida, Sachiro Watanabe, Masanori Kawasaki, Shinya Minatoguchi
Journal: Circulation (2011)

Background: Left atrial (LA) volume is proposed to evaluate left ventricular (LV) filling pressure and E/e' is used to estimate LV diastolic function instead of invasive measurement. However, it is difficult to measure LA volume accurately and quickly using routine echocardiography and E/e' from 8 to 15 is classified as a gray zone to estimate LV filling pressure. Thus, we assessed the hypothesis that evaluation of time-LA volume curve and LA emptying function (EF) measured by speckle tracking may be more useful to estimate LV diastolic function as a noninvasive method in the clinical settings than E/e' . Methods : LA phasic volume and EF were measured in 34 patients (age 69±8, 14 men) with LV ejection fraction ≥50% by speckle tracking echocardiography that can provide time-LA volume curve automatically, and E/e' was also obtained just before cardiac catheterization, and these parameters were compared with pulmonary capillary wedge pressure (PCWP). Results : LA max. and min. volume had significant positive correlations with PCWP (r=0.72, P&lt;0.01 and r=0.80, P&lt;0.01, respectively). LA total, passive and active EF had significant negative correlations with PCWP (r=-0.82, p&lt;0.01, r=-0.56, p&lt;0.05 and r=-0.66, P&lt;0.01, respectively). There was a significant but weak positive correlation between E/e' and PCWP (r=0.52, p&lt;0.05). As PCWP was elevated, LA max. and min. volume were increased and pre-atrial contraction volume was closer to min. volume, and total and active EF were decreased (Figure). Using 33% of LA total EF as a cutoff, the sensitivity and the specificity in predicting elevated LV filling pressure &gt;12mmHg were 89% and 88%, while using 15 of E/e' those values were 53% and 79%, using 40ml/m 2 of LA volume those values were 48% and 82%. Conclusions : In noninvasive estimation of LV diastolic function, assessment of time-LA volume curve and LA EF may be a novel and more useful method and have an incremental value compared with measurement of LA volume and E/e' in the clinical settings .
Abstract 13990: Disturbances of Implantable Cardioverter Defibrillators in Electro-Magnetic Fields. A Clinical Single Center Trial of 102 Patients
Authors: Andreas Napp, Stephan Joosten, Dominik Stunder, Christian Knackstedt, Matthias Zink, Nikolaus Marx, Patrick Schauerte, Jiri Silny
Journal: Circulation (2011)

Objective: Investigations and simulation models indicate that electro magnetic fields (EMF, 50/60 Hz) occurring in daily life may interfere with implanted devices like ICDs. These models can give o...
Abstract 4913: Difference of not only Magnitude but also Heterogeneity of Neointimal Coverage between Drug-Eluting Stent and Bare Metal Stent in Acute Myocardial Infarction
Authors: Masami Nishino, Takahiro Yoshimura, Yasuharu Lee, Daisuke Nakamura, Shinpei Nakatani, Masahiko Hara, Akihito Hashimoto, Kiyoshi Yamagami, Masayuki Taniike, Hiroyasu Kato, Yasuyuki Egami, Ryu Shutta, Hitoshi Yamaguchi, Jun Tanouchi, Yoshio Yamada
Journal: Circulation (2008)

Drug-eluting stent (DES) achieved significant reduced restenosis, however the safety of efficacy of DES in acute myocardial infarction (AMI) are still controversial. In this study, we compared angioscopic parameters between DES and bare metal stent (BMS) in patients with AMI. Eighty-seven consecutive patients who received DES or BMS for AMI were enrolled. At 6-month after AMI, coronary angiography was performed in all patients. We performed coronay angioscope (CAS) if the patients did not show significant in-stent restenosis (&gt;50% stenosis). Using CAS, we evaluated the maximum and minimum grade of neointimal coverage within one stent using the following CAS score: 0: stent struts were exposed similary to right implantaiton, 1: stent were covered by very thin neointima, 2: struts were embedded but visible and 3: struts were fully embedded and invisible. We adopted minimium grade as the magnitude of neointimal coverage and calculated heterogeneity score as the following formula: (maximum grade) − (minimum grade). We compared CAS parameters including magnitude and heterogeneity score of neointimal coverage, visible thrombi and plaque color (white or yellow) aroud stent, and serum parameters including low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, hemoglobin A1c and high sensitive C-reactive protein (hs-CRP). Restnosis rate of DES (n=56) was significantly lower than that of BMS (n=31): 9% vs. 29%, p=0.03. In patients without restenosis, DES group revealed lower magnitude and higher heterogeneity score as compared to BMS group while there were no significant differences of the other parameters between the two groups (table ). Not only lower magnitude but also more heterogeneous propery of neointimal coverage were shown in DES as compared to in BMS at 6-month after AMI. These findings may be correlated with future cardiac evetns while restenosis rate is lower in DES than in BMS.
2型糖尿病病人血糖与大血管和微血管并发症的关系（UKPDS 35）：前瞻性观察研究
Authors: 付勇
Journal: BMJ (2001)

目的 :确定 2型糖尿病病人持续高血糖与发生大血管和微血管并发症危险性之间的关系。研究设计 :前瞻性观察研究。研究单位 :英格兰、苏格兰、北爱尔兰 2 3家临床医院。研究对象 :在英国前瞻性糖尿病研究 (ＵＫＰＤＳ)中的 4 5 84例病人 ,包括白人、亚洲印度人和非洲加勒比人。在发病率的分析中 ,给予随机或不随机处理 ,对其中 3 642例病人进行了相对危险度分析。评估结局的指标 :预先设定的主要临床结局 :任何终点或与糖尿病相关的死亡以及所有致死亡的原因。次要结局 :心肌梗死、中风、截肢 (包括由周围血管疾病引起的死亡 )和微血管疾病 (大多数的视网膜光凝固术 )。单一终点 :非致死性心力
Abstract 5147: GLP-1 Improves Insulin-Stimulated Nitric Oxide-Dependent Vasodilator Responsiveness in Patients With Metabolic Syndrome
Authors: Manfredi Tesauro, Francesca Schinzari, Valentina Rovella, Nadia Mores, Dario Pitocco, Giovanni Ghirlanda, Renato Lauro, Carmine Cardillo
Journal: Circulation (2009)

Our previous work has shown that patients with metabolic syndrome (MetS) have impaired insulin-stimulated vasodilation, which may be involved in the development of hypertension and contribute to insulin resistance by affecting the glucose uptake. Glucagon-like peptide-1 (GLP-1), an amino acid gut hormone that stimulates both insulin secretion and sensitivity, is also provided of cardioprotective and vasoactive properties. We therefore examined the effects of exogenous GLP-1 on insulin-stimulated, nitric oxide (NO)-dependent vasodilation in patients with obesity-related MetS by use of the forearm perfusion technique. Forearm blood flow (FBF) responses to intra-arterial infusion of graded doses of acetylcholine (ACh; stimulus for endothelial release of NO) and sodium nitroprusside (SNP; exogenous NO donor) were assessed in 10 patients with MetS during coinfusion of either saline or regular insulin (0.2 mU/Kg/min). Thereafter, patients underwent to intra-arterial infusion of GLP-1 (30 ng/min for 45 minutes) and responses to ACh and SNP were then reassessed. In the absence of hyperinsulinemia, GLP-1 did not impact unstimulated FBF (from 3.5±0.2 [mean±SEM] to 3.6±0.3 ml/min/dl; P=0.59); similarly, exogenous GLP-1 did not affect vascular responses to both ACh (from 8.8±1.1 to 8.7±1.2 ml/min/dl at the highest dose; P=0.97) and SNP (from 10.7±0.6 to 9.6±0.7 ml/min/dl; P=0.68). In the presence of hyperinsulinemia, GLP-1 infusion was associated with mild increase in basal FBF (from 4.7±0.4 to 5.7±0.6 ml/min/dl; P=0.25); under those conditions, however, exogenous GLP-1 resulted in a significant improvement in vascular reactivity to both ACh (from 13.7±0.7 to 17.4±1.5 ml/min/dl; P=0.03) and SNP (from 12.7±1.0 to 15.9±1.2; P=0.02). In conclusion, exogenous GLP-1 improves both endothelium-dependent and -independent vasodilator responsiveness during hyperinsulinemia in patients with MetS. This suggests that GLP-1 may exert a facilitatory effect on insulin signaling to enhance NO-dependent reactivity in vascular smooth muscle. As a consequence, strategies targeting the GLP-1 system for treatment of type 2 diabetes might beneficially affect both metabolic and hemodynamic abnormalities associated with insulin resistance.
Abstract 16726: False Positive Coronary Angiography Activation in a Primary Coronary Angioplasty Network: Does Direct Ambulance-based Access Influence The Prevalence Rate?
Authors: Enrica Perugini, Claudio Rapezzi, Lara Di Diodoro, Letizia Riva, Paolo Ortolani, Gianni Casella, Nevio Taglieri, Pietro Sangiorgio, Antonio Marzocchi, Angelo Branzi, Giuseppe Di Pasquale
Journal: Circulation (2010)

Purpose: The problem of false positives for ST-segment elevation myocardial infarction (FP-STEMI) is emerging as an unavoidable issue within primary coronary angioplasty (PCI) networks. It is unkno...
Abstract 12548: 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) Treatment Decreases Epicardial and Pericardial Adipose Tissue in Patients with Recent Acute Coronary Syndrome
Authors: Reuben J Ram, Vahid Nabavi Larijani, Ferdinand R Flores, Sachidanand Prabhu, Nina Ram, Michael Baskett, Armand Ardestani, Naser Ahmadi, Jean Grégoire, Josephine Pressacco, Matthew Budoff, Jean-Claude Tardif
Journal: Circulation (2012)

Background: Epicardial adipose tissue (EAT) has been shown to be associated with coronary atherosclerosis and also as a predictor of future adverse cardiovascular events. VIA-2291, a selective 5-Li...
Abstract 3732: Long-Term Safety and Efficacy of ABT-335 (Fenofibric Acid) in Combination with Statin Therapy for the Treatment of Patients with Mixed Dyslipidemia
Authors: Harold E. Bays, Peter H. Jones, Syed M. Mohiuddin, Maureen T. Kelly, Hsiaoming Sun, Carolyn M. Setze, Susan M. Buttler, Darryl J. Sleep, James C. Stolzenbach
Journal: Circulation (2008)

Background: The efficacy and safety of ABT-335 + statin combination therapy was demonstrated in three 12-week, controlled studies of patients with mixed dyslipidemia randomized to ABT-335 (135mg) + low or moderate dose rosuvastatin (R), simvastatin (S), or atorvastatin (A), or ABT-335 or statin monotherapy. A subsequent 52-week open label extension study evaluated the long-term safety and efficacy of ABT-335 combined with statins. Methods: Patients who completed 12 weeks of treatment in the 3 controlled studies were eligible to enroll in the 52-week extension study to receive ABT-335 + the moderate dose statin that was used in their initial study: R 20mg, S 40mg, or A 40mg. This was a pre-specified, integrated analysis of patients receiving ABT-335 + statin in the 12- and 52-week studies. Results: Of the 2715 randomized patients, 2316 completed the 12-week studies and 1911 enrolled in the extension study. A total of 2201 patients received at least 1 dose of ABT-335 + statin for a median duration of 364 days; 1139 patients were treated for ≥52 weeks. The incidence of adverse events (AEs) was similar across all 3 combination therapy groups (Table ). The most common AEs were headache, upper respiratory tract infection, nasopharyngitis, and back pain. Rhabdomyolysis was not reported in any group. Patients who were initially randomized to ABT-335 + statin and continued in the extension study (N=979) had sustained improvements in multiple lipids. After 12 and 52 weeks of treatment, combination therapy resulted in mean percent decreases in TG (−45.7% and −47.5%, respectively) and LDL-C (−32.2% and −37.8%), and increases in HDL-C (17.6% and 23.8%). Mean values at 12 and 52 weeks were: TG 141.2 and 136.3 mg/dL; LDL-C 101.6 and 93.5 mg/dL; and HDL-C 45.0 and 47.1 mg/dL, respectively. Conclusions: Long-term ABT-335 + statin combination therapy was generally well tolerated and resulted in comprehensive and sustained improvements in TG, HDL-C, and LDL-C in adults with mixed dyslipidemia. Summary of safety, n/N (%)
Comorbidity as a driver of adverse outcomes in people with chronic kidney disease
Authors: Marcello Tonelli, Natasha Wiebe, Bruce Guthrie, Matthew T. James, Hude Quan, Martin Fortin, Scott W. Klarenbach, Peter Sargious, Sharon Straus, Richard Lewanczuk, Paul E. Ronksley, Braden J. Manns, Brenda R. Hemmelgarn
Journal: Kidney International (2015)
Direct Imaging of Cerebral Thromboemboli Using Computed Tomography and Fibrin-targeted Gold Nanoparticles
Authors: Jeong-Yeon Kim, Ju Hee Ryu, Dawid Schellingerhout, In-Cheol Sun, Su-Kyoung Lee, Sangmin Jeon, Jiwon Kim, Ick Chan Kwon, Matthias Nahrendorf, Cheol-Hee Ahn, Kwangmeyung Kim, Dong-Eog Kim
Journal: Theranostics (2015)

Computed tomography (CT) is the current standard for time-critical decision-making in stroke patients, informing decisions on thrombolytic therapy with tissue plasminogen activator (tPA), which has a narrow therapeutic index. We aimed to develop a CT-based method to directly visualize cerebrovascular thrombi and guide thrombolytic therapy. Glycol-chitosan-coated gold nanoparticles (GC-AuNPs) were synthesized and conjugated to fibrin-targeting peptides, forming fib-GC-AuNP. This targeted imaging agent and non-targeted control agent were characterized in vitro and in vivo in C57Bl/6 mice (n = 107) with FeCl3-induced carotid thrombosis and/or embolic ischemic stroke. Fibrin-binding capacity was superior with fib-GC-AuNPs compared to GC-AuNPs, with thrombi visualized as high density on microCT (mCT). mCT imaging using fib-GC-AuNP allowed the prompt detection and quantification of cerebral thrombi, and monitoring of tPA-mediated thrombolytic effect, which reflected histological stroke outcome. Furthermore, recurrent thrombosis could be diagnosed by mCT without further nanoparticle administration for up to 3 weeks. fib-GC-AuNP-based direct cerebral thrombus imaging greatly enhance the value and information obtainable by regular CT, has multiple uses in basic / translational vascular research, and will likely allow personalized thrombolytic therapy in clinic by a) optimizing tPA-dosing to match thrombus burden, b) enabling the rational triage of patients to more radical therapies such as endovascular clot-retrieval, and c) potentially serving as a theranostic platform for targeted delivery of concurrent thrombolysis.
Abstract 13294: Outcomes of Patients with Severe Aortic Stenosis at High Surgical Risk Evaluated in a Clinical Trial of Trans-Catheter Aortic Valve Replacement
Authors: Itsik Ben-Dor, Gabriel Maluenda, Israel Barbash, Camille Hauville, Ana Laynez, Michael A. Gaglia, Gabriel Sardi, Petros Okubagzi, Rebecca Torguson, Zhenyi Xue, Joseph Lindsay, William O. Suddath, Kenneth M. Kent, Lowell F. Satler, Augusto D. Pichard, Ron Waksman
Journal: Circulation (2011)

Background: Patient populations with severe aortic stenosis (AS) are at high surgical risk (STS score >10% or Logistic EuroSCORE >20%). Transcatheter-aortic valve replacement (T-AVR) has emerged as a less invasive treatment for these patients. Aim: To assess the outcome and predictors of mortality for patients referred for T-AVR. Methods: From April 2007 to May 2011, a cohort of 900 patients with severe AS were evaluated as candidates for T-AVR. This cohort was divided into three groups: I, medical arm 595 (66.1%) treated medically 241 (26.7%) or by balloon aortic valvuloplasty (BAV) 354 (39.3%); II, surgical arm 146 (16.2%); and III, T-AVR 159 (17.6%). Patients were followed clinically by telephone or office visit. Results: The surgical group had a lower mean age, STS and logistic EuroSCOREs, and incidence of NYHA class IV. The medical/BAV group had significantly higher BNP levels and lower ejection fraction (Table). Mortality rate in the medical/BAV group was 46.6% (n=277) at median (25th, 75th interqua...
P0702 : CC IL28B Genotype is associated with high liver necroinflammation and increased expression of TH1 cytokines (CYK) and chemokines (CHK), but also higher TH2 CYK which may drive low ISG expression
Authors: J.A. Holmes, N. Skinner, M. Congiu, R. Millen, S.J. Bell, T. Nguyen, D.M. Iser, W. Sievert, P.V. Desmond, K. Visvanathan, A.J. Thompson
Journal: Journal of Hepatology (2015)
Abstract 4067: Responses to Symptoms among Older Patients with Acute Myocardial Infarction in Korea
Authors: Seon Young Hwang, Myungja Choi, Myung Ho Jeong
Journal: Circulation (2008)

Background: Older patients’ delay in seeking treatment for symptoms is longer than younger patients with acute myocardial infarction (AMI), and results in increased higher rates of mortality and medical expenses. Objectives: To identify their personal and cognitive responses to symptoms and related actions among older patients aged over 65 years with the first attack of AMI in Korea. Methods: Study sample included 89 older patients hospitalized at a University Hospital, a principal site of Korea Acute Myocardial Infarction Registry. Semi-structured interviews were conducted, after approval of institutional review board, on the 2 nd to 5 th day of their stay in the hospital following coronary intervention, lasted 30 – 40 min and tape-recorded. Results: Median delay time from symptom onset to hospital was 24 ± 136.6 hours and mean age was 73 ± 5.7 years. About 70% had an elementary school education or lower and chronic illnesses such as hypertension or diabetes. The 30% presented to hospital for their atypical symptoms rather than chest pain. Average length of hospital stay was 13 ± 8.3 days. Lower education, intermittent or progressive development of symptoms, and no attribution as cardiac problems increased patient delay. Many patients showed great patience with self-management to alleviate their discomfort in various ways, such as self-medication, letting blood from their finger, and laying down at home. Four describing themes for the delay behaviors emerged from the qualitative data that they had never imagined that they could have a heart attack because they were not sick even if they had hypertension or diabetes, attributed their symptoms to their chronic illnesses or natural complaints of older age, already attempted a medical help for their non-typical symptoms like a flu, and did not want to burden their families or medical expenses with their problems. Conclusions: The findings demonstrated unique coping responses to symptoms in Korean elders. Educational intervention for the elders at high risk group for AMI is needed to increase knowledge of AMI and facilitate their decision to seek immediate help following chest discomfort.
Abstract 20259: Lower Surface Content of L-type Calcium Channel Impairs Cardiac Contractility in Heart Failure Patients
Authors: Ting-Ting Hong, James W Smyth, Kevin Y Chu, Jacob M Vogan, Tina S Fong, Ethan Weiss, Brian C Jenson, Marc Halushka, Stuart D Russell, Karen Ocorr, Charles W Hoopes, Neil C Chi, Robin M Shaw
Journal: Circulation (2010)

Introduction: Heart failure is a growing epidemic, yet the mechanisms by which damaged hearts progress to end-stage disease remain unclear. A typical aspect of failing hearts is altered calcium signaling. The cardiac calcium transient is initiated by L-type calcium channels (Cav1.2). Normal cardiac calcium transient begins with membrane depolarization which initiates calcium entry through T-tubule Cav1.2, triggering a large release of calcium by the intracellular sarcoplasmic reticulum. We recently found that forward trafficking of Cav1.2 channels to T-tubules is facilitated by the membrane curvature and T-tubule protein BIN1. However, Cav1.2 channels trafficking in failing cardiomyocytes remains unidentified.

Hypothesis: In failing cardiomyocytes, there is abnormal Cav1.2 forward trafficking and therefore lower surface content of Cav1.2, resulting in impaired cardiac contractility.

Methods and Results: Using cardiomyocytes isolated from non-failing and end-stage failing human hearts, we found that overall Cav1.2 messenger and protein expression levels are the same by quantitative rt-PCR, immunofluorescence, and western blot. However, in failing hearts, Cav1.2 is internalized. Furthermore, in failing hearts, the protein and message levels of the Cav1.2 T-tubule anchor protein BIN1 are lower, diminishing a key mechanism by which Cav1.2 channels get to T-tubules. In adult mouse cardiomyocytes, lentiviral mediated shRNA knockdown of BIN1 decreases surface level of Cav1.2 and impairs the intracellular calcium transient. In zebrafish hearts, morpholino mediated BIN1 knockdown diminishes the calcium transient and causes severe ventricular dysfunction. From patients with differing stages of idiopathic heart failure, we found that cardiac BIN1 levels are proportional to cardiac output and prognosticate heart failure development.

Conclusions: The data support a model whereby surface membrane localization of Cav1.2 is reduced during heart failure as a result of limited BIN1 expression, impairing the calcium transient and contributing to excitation-contraction uncoupling in human heart failure. This cellular mechanism can help explain heart failure progression and also help prognosticate heart failure outcomes.
Abstract 2559: Impact of Stent Thrombosis On MACE In The ARTS-II Study
Authors: Patrick W Serruys, Joost Daemen, Pascal Vranckx, Peter Smits, Claude Hanet, Jean-Paul Herrman, Kristel Wittebols, Hans-Peter Stoll
Journal: Circulation (2007)

PURPOSE: There is still scarce data about the incidence of (late) stent thrombosis (ST) following implantation of drug-eluting stents in patients treated for multivessel coronary artery disease (MVD). Recent concerns were raised about a possible erosion of the long-term treatment benefit of sirolimus-eluting stents (SES) due to ST. Our aim was to assess the impact of ST on Major Adverse Cardiac Events (MACE) up to 3 years in patients treated with SES for MVD in the Arterial Revascularization Therapies Study part II (ARTS-II) trial. METHODS: ARTS-II is a non-randomized, open label, stratified trial with 607 patients exclusively treated with SES for multivessel coronary artery disease including mandatory involvement of the LAD. The 3-year clinical data from ARTS-II were re-adjudicated by an independent clinical events committee for the incidence of ST according to the definitions recently proposed by an Academic Research Consortium (ARC) using the categories of definite (angiography or autopsy), probable (myocardial infarction in target area, unexplained death within 30 days), and possible ST (unexplained death). RESULTS: The majority of patients (53.5%) had 3-vessel disease. Total stented length was 72.5 ± 32.1mm, and 3.7 ± 1.5 stents were implanted per patient on average. At 3 years, 18/607patients died (3.0%), and MI was observed in 49/607 patients (8.1%). Stent thrombosis occurred in 39/607 patients (6.4%), 21 patients had ``definite” ST, and 32 patients had ``definite or probable” ST according to the ARC classification. From the 39 patients experiencing ST only 8 died, 7 of which were contributed by the ARC ``possible” ST category. CONCLUSIONS: In ARTS-II, the majority of deaths in patients with ST was contributed by the ARC possible category. The final impact of ST on the individual MACE categories will be presented at the conference.
Randomised trial comparing doxorubicin, paclitaxel (AT), versus paclitaxel (T), as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum-based chemotherapy.
Authors: I Floriani, Torri, A Buda, R Rossi, M Cantu, G Parma, N Colombo, P Conte, A Ravaioli
Journal: Annals of Oncology (2000)